(Q46542233)

23 December 2017

title

Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles (English)

1 reference

23 December 2017

1 reference

Beatrice Astruc

1

1 reference

23 December 2017

Peter Marbach

2

1 reference

23 December 2017

Hakim Bouterfa

3

1 reference

23 December 2017

Caroline Denot

4

1 reference

23 December 2017

Mitra Safari

5

1 reference

23 December 2017

Alessandra Vitaliti

6

1 reference

23 December 2017

Michael Sheppard

7

1 reference

23 December 2017

publication date

1 July 2005

1 reference

23 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

23 December 2017

volume

45

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

page(s)

836-844

1 reference

23 December 2017

Somatostatin (second of two parts).

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Molecular pharmacology of somatostatin-receptor subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Molecular pharmacology of somatostatin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Gallbladder sludge: what is its clinical significance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Self-association process of a peptide in solution: from beta-sheet filaments to large embedded nanotubes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

The pathophysiological consequences of somatostatin receptor internalization and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277936

21 January 2018

Identifiers

DOI

10.1177/0091270005277936

1 reference

23 December 2017

1 reference

23 December 2017